CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.

Departments of Medicine and Urology, Michigan Center for Translational Pathology and the University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, United States.
Cytokine & growth factor reviews (Impact Factor: 6.54). 12/2009; 21(1):41-8. DOI: 10.1016/j.cytogfr.2009.11.009
Source: PubMed

ABSTRACT CCL2 is a chemokine known to recruit monocytes and macrophages to sites of inflammation. A growing body of research suggests CCL2 is progressively overexpressed in tumor beds and may play a role in the clinical progression of solid tumors. Cancer cells derived from several solid tumor types demonstrate functional receptors for CCL2, suggesting this chemokine may achieve tumorigenicity through direct effects on malignant cells; however, a variety of normal host cells that co-exist with cancer in the tumor microenvironment also respond to CCL2. These cells include macrophages, osteoclasts, endothelial cells, T-lymphocytes, and myeloid-derived immune suppressor cells (MDSCs). CCL2 mediated interactions between normal and malignant cells in the tumor microenvironment and plays a multi-faceted role in tumor progression.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Endotoxin tolerance (ET) is a state of reduced responsiveness to endotoxin stimulation after a primary bacterial insult. This phenomenon has been described in several pathologies, including sepsis, in which an endotoxin challenge results in reduced cytokine production. In this study, we show that the NFκ L chain enhancer of activated B cells 2 (NFκB2)/p100 was overexpressed and accumulated in a well-established in vitro human monocyte model of ET. The p100 accumulation in these cells inversely correlated with the inflammatory response after LPS stimulation. Knocking down NFκB2/p100 using small interfering RNA in human monocytes further indicated that p100 expression is a crucial factor in the progression of ET. The monocytes derived from patients with sepsis had high levels of p100, and a downregulation of NFκB2/p100 in these septic monocytes reversed their ET status.
    The Journal of Immunology 09/2014; 193(8). DOI:10.4049/jimmunol.1400721 · 5.36 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Rationale: Recent studies indicate that tumor associated macrophages with an M2 phenotype can influence cancer progression and metastasis, but the regulatory pathways remain poorly characterized. Objectives: This study investigated the role of tumor-associated macrophages (MΦ) in lung cancer. Methods and results: Co-culturing of MΦ with mouse Lewis Lung Carcinoma (LLC1) and 10 different human lung cancer cell lines (adenocarcinoma, squamous and large cell carcinoma) caused upregulation of CCR2/CCL2 and CX3CR1/CX3CL1 in both the cancer cells and the MΦ. In the MΦ-tumor cell system, IL-10 drove CCR2 and CX3CR1 upregulation, while CCL1, G-CSF and MIP1α were required for the upregulation of CCL2 and CX3CL1. Downstream phenotypic effects included enhanced LLC1 proliferation and migration and MΦ M2 polarization. In vivo, MΦ depletion (clodronate, MaFIA mice) and genetic ablation of CCR2 and CX3CR1 all inhibited LLC1 tumor growth and metastasis, shifted tumor-associated MΦ towards M1 polarization, suppressed tumor vessel growth and enhanced survival (metastasis model). Furthermore, mice treated with CCR2 antagonist mimicked genetic ablation of CCR2 by reducing tumor growth and metastasis. In human lung cancer samples, tumor MΦ infiltration and CCR2 expression correlated with tumor stage and metastasis. Conclusions: Tumor-associated MΦ play a central role in lung cancer growth and metastasis, with bidirectional crosstalk between MΦ and cancer cells via CCR2- and CX3CR1-signaling as an central underlying mechanism. These findings suggest that the therapeutic strategy of blocking CCR2 and CX3CR1 may prove beneficial for halting lung cancer progression.
    American Journal of Respiratory and Critical Care Medicine 12/2014; DOI:10.1164/rccm.201406-1137OC · 11.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic inflammation is postulated to influence prostate cancer progression. Preclinical studies have claimed that inflammatory mediators are involved in prostate cancer development and therefore suggested these as attractive targets for intervention. However, among the many pro-inflammatory mediators, there is no consensus regarding the identity of the primary one(s). In clinical studies, chronic inflammation has been found in prostate tumor specimens, and tissues resected for treatment of benign prostatic hyperplasia (BPH). Although collective evidence from molecular, experimental and clinical data suggests that inflammation can contribute or promote prostate carcinogenesis, an etiologic link has not yet been established. Moreover, the role of chronic inflammation in the onset of castration resistant and metastatic disease is unclear. Therefore it is important to open a dialog regarding recent findings on how chronic inflammatory mediators contribute to prostate cancer progression, and their usefulness to prevent disease progression. In this review, we assess the current literature with respect to chronic inflammation as a potential initiator and promoter of prostate carcinogenesis and discuss the prospects for its potential clinical applications. Copyright © 2015. Published by Elsevier Inc.
    Biochemical Pharmacology 01/2015; 94(2). DOI:10.1016/j.bcp.2014.12.023 · 4.65 Impact Factor


Available from